Clinical trial results:
A Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multi-Centre Study to Investigate the Safety and Efficacy of CP-690,550 for Maintenance Therapy in Subjects with Moderate to Severe Crohn's Disease

Summary

EudraCT number	2011-001754-28
Trial protocol	DE SE HU ES AT NL CZ GR BG HR
Global end of trial date	29 July 2015

Results information

Result version number	v1 (current)
This version publication date	22 July 2016
First version publication date	22 July 2016

Trial information

Trial identification

Sponsor protocol code	A3921084

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01393899
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Pfizer Inc.
Sponsor organisation address	235 E 42nd Street, New York, United States, NY 10017
Public contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 800-718-1021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 800-718-1021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	29 July 2015
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	29 July 2015
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To estimate the effects of tofacitinib in maintaining clinical response or clinical remission in subjects with moderate to severe Crohn’s disease (CD) who previously achieved clinical response or clinical remission at Week 8 in the induction Study A3921083

Protection of trial subjects:

This study was conducted in compliance with the ethical principles originating in or derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. In addition, all local regulatory requirements were followed, in particular, those affording greater protection to the safety of trial participants.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	12 March 2012
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 6
Country: Number of subjects enrolled	Austria: 3
Country: Number of subjects enrolled	Bulgaria: 3
Country: Number of subjects enrolled	Canada: 8
Country: Number of subjects enrolled	Czech Republic: 1
Country: Number of subjects enrolled	France: 4
Country: Number of subjects enrolled	Germany: 14
Country: Number of subjects enrolled	Greece: 2
Country: Number of subjects enrolled	Hungary: 18
Country: Number of subjects enrolled	Israel: 7
Country: Number of subjects enrolled	Japan: 14
Country: Number of subjects enrolled	Korea, Republic of: 11
Country: Number of subjects enrolled	Netherlands: 3
Country: Number of subjects enrolled	South Africa: 3
Country: Number of subjects enrolled	Spain: 15
Country: Number of subjects enrolled	Ukraine: 7
Country: Number of subjects enrolled	United States: 61
Worldwide total number of subjects	180
EEA total number of subjects	63

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	176
From 65 to 84 years	4
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

A total of 180 subjects were randomized to the study

Pre-assignment

Screening details:

Baseline visit for this study took place on the same day as the Study A3921083 Week 8 visit. Participants who achieved clinical response-100 and/or clinical remission after completion of the 8-week induction therapy in Study A3921083 and who fulfilled the inclusion/exclusion criteria were randomly assigned to 1 of 3 treatments of this study.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Investigator, Monitor, Subject, Carer, Data analyst, Assessor

Blinding implementation details:

Study treatment assignment was blinded to participants, investigators, and the sponsor. Assignment of participant identification number and study drug, site drug inventory control and emergency unblinding, were managed through a telerandomization tool. At the initiation of the study, the study site was instructed on how to use the telerandomization tool to break the blind, and each study site was provided a manual containing complete instructions for web or telephone access.

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo

Arm description:

Placebo (two placebo tablets) to match tofacitinib for oral administration BID for 26 weeks.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Two placebo tablets were administered orally BID for 26 weeks.

Arm title	Tofacitinib 5 mg BID

Arm description:

Tofacitinib 5 mg (one placebo tablet and one tofacitinib tablet) for oral administration at a dose of 5 mg BID for 26 weeks.

Arm type	Experimental
Investigational medicinal product name	Tofacitinib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Tofacitinib 5 mg (one placebo tablet and one tofacitinib tablet) were administered orally BID for 26 weeks.

Arm title	Tofacitinib 10 mg BID

Arm description:

Tofacitinib 10 mg (two tofacitinib tablets) for oral administration at a dose of 10 mg BID for 26 weeks.

Arm type	Experimental
Investigational medicinal product name	Tofacitinib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Tofacitinib 10 mg (two tofacitinib tablets) were administered orally BID for 26 weeks.

Number of subjects in period 1	Placebo	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID
Started	59	60	61
Completed	27	32	38
Not completed	32	28	23
Consent withdrawn by subject	2	2	1
Does not meet entrance criteria	1	-	1
Adverse event, non-fatal	1	5	3
Study terminated by sponsor	1	-	1
Unspecified	1	-	-
Lost to follow-up	-	-	1
Lack of efficacy	26	21	16

Baseline characteristics

Reporting groups	
Reporting group title	Placebo
Reporting group description:	
Placebo (two placebo tablets) to match tofacitinib for oral administration BID for 26 weeks.	
Reporting group title	Tofacitinib 5 mg BID
Reporting group description:	
Tofacitinib 5 mg (one placebo tablet and one tofacitinib tablet) for oral administration at a dose of 5 mg BID for 26 weeks.	
Reporting group title	Tofacitinib 10 mg BID
Reporting group description:	
Tofacitinib 10 mg (two tofacitinib tablets) for oral administration at a dose of 10 mg BID for 26 weeks.	

Reporting group values	Placebo	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID
Number of subjects	59	60	61
Age, Customized Units: Participants			
Less than or equal to (<=)18 years	0	0	0
Between 18 and 44 years	34	44	40
Between 45 and 64 years	23	15	20
More than or equal to (>=)65 years	2	1	1
Age continuous Units: years			
arithmetic mean	41.5	38.1	39
standard deviation	± 12.8	± 11.9	± 13.1
Gender, Male/Female Units: Participants			
Female	32	30	24
Male	27	30	37

Reporting group values	Total		
Number of subjects	180		
Age, Customized Units: Participants			
Less than or equal to (<=)18 years	0		
Between 18 and 44 years	118		
Between 45 and 64 years	58		
More than or equal to (>=)65 years	4		
Age continuous Units: years			
arithmetic mean			
standard deviation	-		
Gender, Male/Female Units: Participants			
Female	86		
Male	94		

End points

End points reporting groups

Reporting group title	Placebo
Reporting group description:	
Placebo (two placebo tablets) to match tofacitinib for oral administration BID for 26 weeks.	
Reporting group title	Tofacitinib 5 mg BID
Reporting group description:	
Tofacitinib 5 mg (one placebo tablet and one tofacitinib tablet) for oral administration at a dose of 5 mg BID for 26 weeks.	
Reporting group title	Tofacitinib 10 mg BID
Reporting group description:	
Tofacitinib 10 mg (two tofacitinib tablets) for oral administration at a dose of 10 mg BID for 26 weeks.	

Primary: Percentage of Participants With Clinical Response-100 (as Defined by a Decrease in Crohn's Disease Activity Index [CDAI] Score of at Least 100 Points from Baseline) or Clinical Remission (CDAI Score less than [<]150) at Week 26

End point title	Percentage of Participants With Clinical Response-100 (as Defined by a Decrease in Crohn's Disease Activity Index [CDAI] Score of at Least 100 Points from Baseline) or Clinical Remission (CDAI Score less than [<]150) at Week 26

End point description:

Clinical response-100 was defined as a reduction in CDAI score of at least 100 points from baseline of the parent A3921083 study. Clinical remission was a CDAI score <150 points. CDAI is a composite index consisting of a weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extra-intestinal symptoms, need for anti-diarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's diary kept while on study. CDAI scores range from 0 to approximately 600, higher score indicates higher disease activity.

End point type	Primary

End point timeframe:

Week 26

End point values	Placebo	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	42	43	43	
Units: Percentage of participants				
number (confidence interval 80%)	38.1 (27.94 to 49.16)	39.53 (29.39 to 50.46)	55.81 (44.92 to 66.28)	

Statistical analyses

Statistical analysis title	Analysis of Clinical Response-100
Comparison groups	Placebo v Tofacitinib 5 mg BID

Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	1.44
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-12.11
upper limit	14.99

Statistical analysis title	Analysis of Clinical Response-100
Comparison groups	Placebo v Tofacitinib 10 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Median difference (final values)
Point estimate	17.72
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	4.07
upper limit	31.37

Secondary: Percentage of Participants With Clinical Response-100 or Clinical Remission at Weeks 4, 8, 12 and 20

End point title	Percentage of Participants With Clinical Response-100 or Clinical Remission at Weeks 4, 8, 12 and 20

End point description:

Clinical response-100 was defined as a reduction in CDAI score of at least 100 points from baseline of the parent A3921083 study. Clinical remission was a CDAI score <150 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for anti-diarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.

End point type	Secondary

End point timeframe:

Weeks 4, 8, 12 and 20

End point values	Placebo	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	42	43	43	
Units: Percentage of participants				
number (confidence interval 80%)				

Week 4	73.81 (63.16 to 82.62)	74.42 (63.96 to 83.05)	79.07 (68.98 to 86.96)	
Week 8	66.67 (55.69 to 76.37)	67.44 (56.64 to 76.95)	58.14 (47.22 to 68.46)	
Week 12	50 (39.12 to 60.88)	55.81 (44.92 to 66.28)	53.49 (42.64 to 64.08)	
Week 20	40.48 (30.13 to 51.55)	39.53 (29.39 to 50.46)	51.16 (40.38 to 61.86)	

Statistical analyses

Statistical analysis title	Analysis of Clinical Response-100
Statistical analysis description:	
Week 4	
Comparison groups	Placebo v Tofacitinib 5 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	0.61
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-11.57
upper limit	12.79

Statistical analysis title	Analysis of Clinical Response-100
Statistical analysis description:	
Week 8	
Comparison groups	Placebo v Tofacitinib 5 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	0.78
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-12.29
upper limit	13.84

Statistical analysis title	Analysis of Clinical Response-100
Statistical analysis description:	
Week 12	
Comparison groups	Placebo v Tofacitinib 5 mg BID

Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	5.81
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-8.04
upper limit	19.67

Statistical analysis title	Analysis of Clinical Response-100
Statistical analysis description:	
Week 20	
Comparison groups	Placebo v Tofacitinib 5 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	-0.94
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-14.56
upper limit	12.68

Statistical analysis title	Analysis of Clinical Response-100
Statistical analysis description:	
Week 4	
Comparison groups	Placebo v Tofacitinib 10 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	5.26
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-6.52
upper limit	17.04

Statistical analysis title	Analysis of Clinical Response-100
Statistical analysis description:	
Week 8	

Comparison groups	Placebo v Tofacitinib 10 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	-8.53
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-21.94
upper limit	4.88

Statistical analysis title	Analysis of Clinical Response-100
Statistical analysis description: Week 12	
Comparison groups	Placebo v Tofacitinib 10 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	3.49
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-10.4
upper limit	17.37

Statistical analysis title	Analysis of Clinical Response-100
Statistical analysis description: Week 20	
Comparison groups	Placebo v Tofacitinib 10 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	10.69
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-3.08
upper limit	24.46

Secondary: Percentage of Participants Achieving Clinical Response-100 at Weeks 4, 8, 12, 20 and 26

End point title	Percentage of Participants Achieving Clinical Response-100 at Weeks 4, 8, 12, 20 and 26

End point description:

Clinical response-100 was defined as a reduction in CDAI score from baseline of at least 100 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for anti-diarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.

End point type	Secondary

End point timeframe:

Weeks 4, 8, 12, 20 and 26

End point values	Placebo	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	42	43	43	
Units: Percentage of participants				
number (confidence interval 80%)				
Week 4	73.81 (63.16 to 82.62)	72.09 (61.49 to 81.04)	76.74 (66.45 to 85.02)	
Week 8	66.67 (55.69 to 76.37)	62.79 (51.88 to 72.75)	58.14 (47.22 to 68.46)	
Week 12	50 (39.12 to 60.88)	55.81 (44.92 to 66.28)	51.16 (40.38 to 61.86)	
Week 20	38.1 (27.94 to 49.16)	39.53 (29.39 to 50.46)	51.16 (40.38 to 61.86)	
Week 26	35.71 (25.77 to 46.74)	37.21 (27.25 to 48.12)	55.81 (44.92 to 66.28)	

Statistical analyses

Statistical analysis title	Analysis of Clinical Response-100

Statistical analysis description:

Week 4

Comparison groups	Placebo v Tofacitinib 5 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	-1.72
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-14.06
upper limit	10.63

Statistical analysis title	Analysis of Clinical Response-100

Statistical analysis description: Week 8	
Comparison groups	Placebo v Tofacitinib 5 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	-3.88
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-17.15
upper limit	9.4

Statistical analysis title	Analysis of Clinical Response-100
Statistical analysis description: Week 12	
Comparison groups	Placebo v Tofacitinib 5 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	5.81
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-8.04
upper limit	19.67

Statistical analysis title	Analysis of Clinical Response-100
Statistical analysis description: Week 20	
Comparison groups	Placebo v Tofacitinib 5 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	1.44
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-12.11
upper limit	14.99

Statistical analysis title	Analysis of Clinical Response-100
Statistical analysis description: Week 26	
Comparison groups	Placebo v Tofacitinib 5 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	1.5
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-11.88
upper limit	14.87

Statistical analysis title	Analysis of Clinical Response-100
Statistical analysis description: Week 4	
Comparison groups	Placebo v Tofacitinib 10 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	2.93
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-9.06
upper limit	14.92

Statistical analysis title	Analysis of Clinical Response-100
Statistical analysis description: Week 8	
Comparison groups	Placebo v Tofacitinib 10 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	-8.53
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-21.94
upper limit	4.88

Statistical analysis title	Analysis of Clinical Response-100
Statistical analysis description: Week 12	
Comparison groups	Placebo v Tofacitinib 10 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	1.16
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-12.74
upper limit	15.06

Statistical analysis title	Analysis of Clinical Response-100
Statistical analysis description: Week 20	
Comparison groups	Placebo v Tofacitinib 10 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	13.07
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-0.63
upper limit	26.77

Statistical analysis title	Analysis of Clinical Response-100
Statistical analysis description: Week 26	
Comparison groups	Placebo v Tofacitinib 10 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	20.1

Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	6.54
upper limit	33.66

Secondary: Percentage of Participants in Clinical Remission at Weeks 4, 8, 12, 20 and 26

End point title	Percentage of Participants in Clinical Remission at Weeks 4, 8, 12, 20 and 26

End point description:

Clinical remission was a CDAI score <150 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for anti-diarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.

End point type	Secondary

End point timeframe:

Weeks 4, 8, 12, 20 and 26

End point values	Placebo	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	42	43	43	
Units: Percentage of participants				
number (confidence interval 80%)				
Week 4	52.38 (41.42 to 63.16)	55.81 (44.92 to 66.28)	58.14 (47.22 to 68.46)	
Week 8	47.62 (36.84 to 58.58)	48.84 (38.14 to 59.62)	39.53 (29.39 to 50.46)	
Week 12	33.33 (23.63 to 44.31)	46.51 (35.92 to 57.36)	34.88 (25.14 to 45.75)	
Week 20	30.95 (21.52 to 41.84)	32.56 (23.05 to 43.36)	39.53 (29.39 to 50.46)	
Week 26	28.57 (19.43 to 39.35)	37.21 (27.25 to 48.12)	41.86 (31.54 to 52.78)	

Statistical analyses

Statistical analysis title	Analysis of Clinical Remission

Statistical analysis description:

Week 4

Comparison groups	Placebo v Tofacitinib 5 mg BID

Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	3.43
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-10.41
upper limit	17.28

Statistical analysis title	Analysis of Clinical Remission
Statistical analysis description:	
Week 8	
Comparison groups	Placebo v Tofacitinib 5 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	1.22
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-12.67
upper limit	15.11

Statistical analysis title	Analysis of Clinical Remission
Statistical analysis description:	
Week 12	
Comparison groups	Placebo v Tofacitinib 5 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	13.18
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-0.31
upper limit	26.67

Statistical analysis title	Analysis of Clinical Remission
Statistical analysis description:	
Week 20	

Comparison groups	Placebo v Tofacitinib 5 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	1.61
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-11.33
upper limit	14.55

Statistical analysis title	Analysis of Clinical Remission
Statistical analysis description: Week 26	
Comparison groups	Placebo v Tofacitinib 5 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	8.64
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-4.36
upper limit	21.64

Statistical analysis title	Analysis of Clinical Remission
Statistical analysis description: Week 4	
Comparison groups	Placebo v Tofacitinib 10 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	5.76
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-8.04
upper limit	19.56

Statistical analysis title	Analysis of Clinical Remission

Statistical analysis description: Week 8	
Comparison groups	Placebo v Tofacitinib 10 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	-8.08
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-21.83
upper limit	5.66

Statistical analysis title	Analysis of Clinical Remission
Statistical analysis description: Week 12	
Comparison groups	Placebo v Tofacitinib 10 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	1.55
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-11.63
upper limit	14.73

Statistical analysis title	Analysis of Clinical Remission
Statistical analysis description: Week 20	
Comparison groups	Placebo v Tofacitinib 10 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	8.58
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-4.64
upper limit	21.81

Statistical analysis title	Analysis of Clinical Remission
Statistical analysis description:	
Week 26	
Comparison groups	Placebo v Tofacitinib 10 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	13.29
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	0.15
upper limit	26.43

Secondary: Percentage of Participants in Clinical Remission at Week 4, 8, 12, 20 and 26 Among Participants in Remission at Baseline of Maintenance Study

End point title	Percentage of Participants in Clinical Remission at Week 4, 8, 12, 20 and 26 Among Participants in Remission at Baseline of Maintenance Study
End point description:	
Clinical remission was a CDAI score <150 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for anti-diarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.	
End point type	Secondary
End point timeframe:	
Weeks 4, 8, 12, 20 and 26	

End point values	Placebo	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	25	28	26	
Units: Percentage of participants				
number (confidence interval 80%)				
Week 4	72 (57.42 to 83.68)	78.57 (65.41 to 88.34)	80.77 (67.23 to 90.34)	
Week 8	64 (49.2 to 76.97)	64.29 (50.42 to 76.5)	50 (35.93 to 64.07)	
Week 12	40 (26.53 to 54.77)	64.29 (50.42 to 76.5)	42.31 (28.86 to 56.71)	
Week 20	36 (23.03 to 50.8)	42.86 (29.87 to 56.67)	46.15 (32.36 to 60.43)	
Week 26	28 (16.32 to 42.58)	39.29 (26.65 to 53.16)	50 (35.93 to 64.07)	

Statistical analyses

Statistical analysis title	Analysis of Clinical Remission
Statistical analysis description: Week 4	
Comparison groups	Placebo v Tofacitinib 5 mg BID
Number of subjects included in analysis	53
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	6.57
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-8.63
upper limit	21.78

Statistical analysis title	Analysis of Clinical Remission
Statistical analysis description: Week 8	
Comparison groups	Placebo v Tofacitinib 5 mg BID
Number of subjects included in analysis	53
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	0.29
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-16.63
upper limit	17.2

Statistical analysis title	Analysis of Clinical Remission
Statistical analysis description: Week 12	
Comparison groups	Placebo v Tofacitinib 5 mg BID
Number of subjects included in analysis	53
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	24.29
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	7.19
upper limit	41.38

Statistical analysis title	Analysis of Clinical Remission
Statistical analysis description: Week 20	
Comparison groups	Placebo v Tofacitinib 5 mg BID
Number of subjects included in analysis	53
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	6.86
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-10.32
upper limit	24.03

Statistical analysis title	Analysis of Clinical Remission
Statistical analysis description: Week 26	
Comparison groups	Placebo v Tofacitinib 5 mg BID
Number of subjects included in analysis	53
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	11.29
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-5.22
upper limit	27.79

Statistical analysis title	Analysis of Clinical Remission
Statistical analysis description: Week 4	
Comparison groups	Placebo v Tofacitinib 10 mg BID
Number of subjects included in analysis	51
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	8.77

Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-6.41
upper limit	23.95

Statistical analysis title	Analysis of Clinical Remission
Statistical analysis description: Week 8	
Comparison groups	Placebo v Tofacitinib 10 mg BID
Number of subjects included in analysis	51
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	-14
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-31.59
upper limit	3.59

Statistical analysis title	Analysis of Clinical Remission
Statistical analysis description: Week 12	
Comparison groups	Placebo v Tofacitinib 10 mg BID
Number of subjects included in analysis	51
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	2.31
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-15.35
upper limit	19.97

Statistical analysis title	Analysis of Clinical Remission
Statistical analysis description: Week 20	
Comparison groups	Placebo v Tofacitinib 10 mg BID

Number of subjects included in analysis	51
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	10.15
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-7.41
upper limit	27.71

Statistical analysis title	Analysis of Clinical Remission
Statistical analysis description:	
Week 26	
Comparison groups	Placebo v Tofacitinib 10 mg BID
Number of subjects included in analysis	51
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	22
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	4.96
upper limit	39.04

Secondary: Percentage of Participants in Sustained Clinical Remission (Defined as Being in Clinical Remission at both Weeks 20 and 26) in the Maintenance Phase

End point title	Percentage of Participants in Sustained Clinical Remission (Defined as Being in Clinical Remission at both Weeks 20 and 26) in the Maintenance Phase

End point description:

Clinical remission was a CDAI score <150 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for anti-diarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.

End point type	Secondary

End point timeframe:

Weeks 20 and 26

End point values	Placebo	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	42	43	43	
Units: Percentage of participants				
number (confidence interval 80%)	21.43 (13.37 to 31.71)	23.26 (14.98 to 33.55)	39.53 (29.39 to 50.46)	

Statistical analyses

Statistical analysis title	Analysis of Clinical Remission
Comparison groups	Placebo v Tofacitinib 5 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	1.83
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-9.75
upper limit	13.4

Statistical analysis title	Analysis of Clinical Remission
Comparison groups	Placebo v Tofacitinib 10 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	18.11
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	5.57
upper limit	30.64

Secondary: Percentage of Participants With Sustained Clinical Response-100 (Defined as Having at least a Clinical Response-100 at both Weeks 20 and 26 from the A3921083 Baseline) in the Maintenance Phase

End point title	Percentage of Participants With Sustained Clinical Response-100 (Defined as Having at least a Clinical Response-100 at both Weeks 20 and 26 from the A3921083 Baseline) in the Maintenance Phase

End point description:

Clinical response-100 was defined as a reduction in CDAI score from baseline of at least 100 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very

soft stools, extent of abdominal pain, general well-being, occurrence of extra-intestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.

End point type	Secondary
End point timeframe:	
Weeks 20 and 26	

End point values	Placebo	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	42	43	43	
Units: Percentage of participants				
number (confidence interval 80%)	33.33 (23.63 to 44.31)	25.58 (16.95 to 36.04)	51.16 (40.38 to 61.86)	

Statistical analyses

Statistical analysis title	Analysis of Clinical Response-100
Comparison groups	Placebo v Tofacitinib 5 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	-7.75
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-20.39
upper limit	4.88

Statistical analysis title	Analysis of Clinical Response-100
Comparison groups	Placebo v Tofacitinib 10 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	17.83
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	4.33
upper limit	31.33

Secondary: CDAI Score by Week

End point title	CDAI Score by Week

End point description:

CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general wellbeing, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity

End point type	Secondary

End point timeframe:

Baseline and Weeks 4, 8, 12, 20 and 26

End point values	Placebo	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	42	43	43	
Units: Score on a scale				
arithmetic mean (standard deviation)				
Baseline	135.05 (± 69.83)	127.23 (± 60.46)	133.98 (± 63.31)	
Week 4	168.24 (± 103.18)	133.48 (± 89.94)	143.45 (± 84.26)	
Week 8	171.87 (± 109.18)	149.78 (± 99.56)	165.69 (± 95.46)	
Week 12	181.38 (± 108.68)	158.56 (± 119.41)	152.93 (± 82.77)	
Week 20	161.76 (± 91.65)	151.74 (± 106.09)	112.32 (± 85.47)	
Week 26	137.05 (± 77.65)	134.77 (± 80.22)	110.77 (± 76.3)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in CDAI Score by Week

End point title	Change from Baseline in CDAI Score by Week

End point description:

CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general wellbeing, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity

End point type	Secondary

End point timeframe:

Weeks 4, 8, 12, 20 and 26

End point values	Placebo	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	42	43	43	
Units: Score on a scale				
arithmetic mean (standard deviation)				
Week 4	33.17 (± 76.41)	5.85 (± 69.52)	11.02 (± 72.22)	
Week 8	39.85 (± 83.68)	20.32 (± 69.59)	35.83 (± 101.96)	
Week 12	52.81 (± 113.91)	32.29 (± 88.35)	24.07 (± 84.46)	
Week 20	32.44 (± 96.18)	36.83 (± 90.92)	-14.36 (± 78.58)	
Week 26	1.5 (± 93.91)	17.36 (± 79.81)	-16.35 (± 75.65)	

Statistical analyses

Statistical analysis title	Analysis of CDAI Score
Statistical analysis description: Week 4	
Comparison groups	Placebo v Tofacitinib 5 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0637
Method	Linear mixed-effects model
Parameter estimate	Adjusted Mean Difference
Point estimate	-30.26
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-51.1
upper limit	-9.42

Statistical analysis title	Analysis of CDAI Score
Statistical analysis description: Week 8	
Comparison groups	Placebo v Tofacitinib 5 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.3054
Method	Linear mixed-effects model
Parameter estimate	Adjusted Mean Difference
Point estimate	-21.06

Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-47.43
upper limit	5.31

Statistical analysis title	Analysis of CDAI Score
Statistical analysis description: Week 12	
Comparison groups	Placebo v Tofacitinib 5 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.1316
Method	Linear mixed-effects model
Parameter estimate	Adjusted Mean Difference
Point estimate	-42.52
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-78.57
upper limit	-6.48

Statistical analysis title	Analysis of CDAI Score
Statistical analysis description: Week 20	
Comparison groups	Placebo v Tofacitinib 5 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.5704
Method	Linear mixed-effects model
Parameter estimate	Adjusted Mean Difference
Point estimate	-18.01
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-59.01
upper limit	22.99

Statistical analysis title	Analysis of CDAI Score
Statistical analysis description: Week 26	
Comparison groups	Placebo v Tofacitinib 5 mg BID

Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.8389
Method	Linear mixed-effects model
Parameter estimate	Adjusted Mean Difference
Point estimate	-6
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-44.22
upper limit	32.21

Statistical analysis title	Analysis of CDAI Score
Statistical analysis description:	
Week 4	
Comparison groups	Placebo v Tofacitinib 10 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.1452
Method	Linear mixed-effects model
Parameter estimate	Adjusted Mean Difference
Point estimate	-23.56
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-44.27
upper limit	-2.85

Statistical analysis title	Analysis of CDAI Score
Statistical analysis description:	
Week 8	
Comparison groups	Placebo v Tofacitinib 10 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.6399
Method	Linear mixed-effects model
Parameter estimate	Adjusted Mean Difference
Point estimate	-9.61
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-36.03
upper limit	16.81

Statistical analysis title	Analysis of CDAI Score
Statistical analysis description: Week 12	
Comparison groups	Placebo v Tofacitinib 10 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.1949
Method	Linear mixed-effects model
Parameter estimate	Adjusted Mean Difference
Point estimate	-37
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-73.57
upper limit	-0.42

Statistical analysis title	Analysis of CDAI Score
Statistical analysis description: Week 20	
Comparison groups	Placebo v Tofacitinib 10 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.1358
Method	Linear mixed-effects model
Parameter estimate	Adjusted Mean Difference
Point estimate	-47.74
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-88.62
upper limit	-6.87

Statistical analysis title	Analysis of CDAI Score
Statistical analysis description: Week 26	
Comparison groups	Placebo v Tofacitinib 10 mg BID

Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.089
Method	Linear mixed-effects model
Parameter estimate	Adjusted Mean Difference
Point estimate	-50.38
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-88.03
upper limit	-12.72

Secondary: Kaplan-Meier Estimate of the Rate of Time to Relapse

End point title	Kaplan-Meier Estimate of the Rate of Time to Relapse

End point description:

Time to relapse was defined as increase in CDAI of more than (>)100 points from the maintenance phase baseline and a CDAI score of >220 points, or an increase to or above the baseline CDAI score in A3921083. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general wellbeing, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.

End point type	Secondary

End point timeframe:

Weeks 4, 8 12, 20 and 26

End point values	Placebo	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	42	43	43	
Units: Percentage of participants				
number (confidence interval 80%)				
Week 4 (n=35,38,38)	14.58 (8.42 to 22.37)	7.14 (3.15 to 13.34)	11.63 (6.3 to 18.73)	
Week 8 (n=32,35,32)	21.9 (14.27 to 30.6)	14.47 (8.35 to 22.21)	23.51 (15.73 to 32.21)	
Week 12 (n=24,30,27)	39.18 (29.4 to 48.8)	26.69 (18.32 to 35.77)	31.09 (22.19 to 40.38)	
Week 20 (n=19,22,23)	51.85 (41.33 to 61.37)	39.11 (29.35 to 48.74)	38.95 (29.16 to 48.6)	
Week 26 (n=1,1,2)	69.59 (48.73 to 83.29)	50.69 (38.96 to 61.27)	43.31 (32.6 to 53.54)	

Statistical analyses

Statistical analysis title	Analysis of Time to Relapse

Statistical analysis description: Week 4	
Comparison groups	Placebo v Tofacitinib 5 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	-7.44
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-16.14
upper limit	1.26

Statistical analysis title	Analysis of Time to Relapse
Statistical analysis description: Week 8	
Comparison groups	Placebo v Tofacitinib 5 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	-7.43
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-18.27
upper limit	3.41

Statistical analysis title	Analysis of Time to Relapse
Statistical analysis description: Week 12	
Comparison groups	Placebo v Tofacitinib 5 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	-12.48
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-25.68
upper limit	0.72

Statistical analysis title	Analysis of Time to Relapse
Statistical analysis description: Week 20	
Comparison groups	Placebo v Tofacitinib 5 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	-12.73
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-26.81
upper limit	1.34

Statistical analysis title	Analysis of Time to Relapse
Statistical analysis description: Week 26	
Comparison groups	Placebo v Tofacitinib 5 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	-18.9
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-39.52
upper limit	1.72

Statistical analysis title	Analysis of Time to Relapse
Statistical analysis description: Week 4	
Comparison groups	Placebo v Tofacitinib 10 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	-2.96
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-12.39
upper limit	6.48

Statistical analysis title	Analysis of Time to Relapse
Statistical analysis description: Week 8	
Comparison groups	Placebo v Tofacitinib 10 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	1.61
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-10.14
upper limit	13.36

Statistical analysis title	Analysis of Time to Relapse
Statistical analysis description: Week 12	
Comparison groups	Placebo v Tofacitinib 10 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	-8.09
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-21.54
upper limit	5.36

Statistical analysis title	Analysis of Time to Relapse
Statistical analysis description: Week 20	
Comparison groups	Placebo v Tofacitinib 10 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	-12.9

Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-26.99
upper limit	1.19

Statistical analysis title	Analysis of Time to Relapse
Statistical analysis description:	
Week 26	
Comparison groups	Placebo v Tofacitinib 10 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	-26.28
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-46.54
upper limit	-6.02

Secondary: Percentage of Participants Achieving a Steroid-Free Clinical Remission at Week 26 of the Maintenance Phase - Among Participants on Steroids at A3921084 Baseline

End point title	Percentage of Participants Achieving a Steroid-Free Clinical Remission at Week 26 of the Maintenance Phase - Among Participants on Steroids at A3921084 Baseline
End point description:	
Clinical remission was a CDAI <150 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general wellbeing, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body eight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.	
End point type	Secondary
End point timeframe:	
Week 26	

End point values	Placebo	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	12	11	15	
Units: Percentage of participants				
number (confidence interval 80%)	16.67 (4.52 to 38.55)	27.27 (10.48 to 51.08)	33.33 (17.2 to 53.17)	

Statistical analyses

Statistical analysis title	Analysis of Clinical Remission
Comparison groups	Placebo v Tofacitinib 10 mg BID
Number of subjects included in analysis	27
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	16.67
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-4.15
upper limit	37.49

Statistical analysis title	Analysis of Clinical Remission
Comparison groups	Placebo v Tofacitinib 5 mg BID
Number of subjects included in analysis	23
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (final values)
Point estimate	10.61
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-11.44
upper limit	32.66

Secondary: C-Reactive Protein (CRP) by Week	
End point title	C-Reactive Protein (CRP) by Week
End point description:	
The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.	
End point type	Secondary
End point timeframe:	
Baseline and Weeks 4, 8, 12, 20 and 26	

End point values	Placebo	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	42	43	43	
Units: milligram per liter (mg/L)				
arithmetic mean (standard deviation)				
Baseline	8.08 (± 13.88)	7.08 (± 10.83)	8.59 (± 16.43)	
Week 4	16.08 (± 24.62)	8.04 (± 17.36)	7.62 (± 15.03)	
Week 8	15.8 (± 28.98)	8.03 (± 10.86)	7.24 (± 16.48)	
Week 12	15.49 (± 17.8)	8.19 (± 11.75)	5.57 (± 13.52)	
Week 20	15.1 (± 20.37)	10.07 (± 14.56)	6.52 (± 18.26)	
Week 26	27.7 (± 41.76)	13 (± 13.65)	3.57 (± 3.55)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in CRP by Week

End point title	Change from Baseline in CRP by Week

End point description:

The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.

End point type	Secondary

End point timeframe:

Weeks 4, 8, 12, 20 and 26

End point values	Placebo	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	42	43	43	
Units: milligram per liter (mg/L)				
arithmetic mean (standard deviation)				
Week 4	10.66 (± 19.47)	0.84 (± 12.52)	-0.97 (± 10.81)	
Week 8	10.33 (± 24.33)	0.96 (± 9.8)	1.29 (± 7.24)	
Week 12	11.78 (± 17.85)	2.36 (± 12.15)	0.39 (± 3.66)	
Week 20	11.48 (± 19.25)	2.92 (± 14.86)	0.91 (± 6.75)	
Week 26	24.07 (± 40.9)	6.62 (± 13.07)	0.59 (± 3.75)	

Statistical analyses

Statistical analysis title	Analysis of CRP
Statistical analysis description: Week 4	
Comparison groups	Placebo v Tofacitinib 5 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.0001
Method	Linear mixed-effects model
Parameter estimate	Adjusted Mean Difference
Point estimate	-0.93
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.34
upper limit	-0.53

Statistical analysis title	Analysis of CRP
Statistical analysis description: Week 8	
Comparison groups	Placebo v Tofacitinib 5 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0024
Method	Linear mixed-effects model
Parameter estimate	Adjusted Mean Difference
Point estimate	-0.76
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.24
upper limit	-0.28

Statistical analysis title	Analysis of CRP
Statistical analysis description: Week 12	
Comparison groups	Placebo v Tofacitinib 5 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0044
Method	Linear mixed-effects model
Parameter estimate	Adjusted Mean Difference
Point estimate	-0.75

Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.26
upper limit	-0.24

Statistical analysis title	Analysis of CRP
Statistical analysis description:	
Week 20	
Comparison groups	Placebo v Tofacitinib 5 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0582
Method	Linear mixed-effects model
Parameter estimate	Adjusted Mean Difference
Point estimate	-0.56
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.13
upper limit	0.02

Statistical analysis title	Analysis of CRP
Statistical analysis description:	
Week 26	
Comparison groups	Placebo v Tofacitinib 5 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0865
Method	Linear mixed-effects model
Parameter estimate	Adjusted Mean Difference
Point estimate	-0.61
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.31
upper limit	0.09

Statistical analysis title	Analysis of CRP
Statistical analysis description:	
Week 4	
Comparison groups	Placebo v Tofacitinib 10 mg BID

Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.0001
Method	Linear mixed-effects model
Parameter estimate	Adjusted Mean Difference
Point estimate	-0.92
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.32
upper limit	-0.52

Statistical analysis title	Analysis of CRP
Statistical analysis description: Week 8	
Comparison groups	Placebo v Tofacitinib 10 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0002
Method	Linear mixed-effects model
Parameter estimate	Adjusted Mean Difference
Point estimate	-0.92
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.4
upper limit	-0.45

Statistical analysis title	Analysis of CRP
Statistical analysis description: Week 12	
Comparison groups	Placebo v Tofacitinib 10 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.0001
Method	Linear mixed-effects model
Parameter estimate	Adjusted Mean Difference
Point estimate	-1.23
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.75
upper limit	-0.71

Statistical analysis title	Analysis of CRP
Statistical analysis description: Week 20	
Comparison groups	Placebo v Tofacitinib 10 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.0001
Method	Linear mixed-effects model
Parameter estimate	Adjusted Mean Difference
Point estimate	-1.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.87
upper limit	-0.74

Statistical analysis title	Analysis of CRP
Statistical analysis description: Week 26	
Comparison groups	Placebo v Tofacitinib 10 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.0001
Method	Linear mixed-effects model
Parameter estimate	Adjusted Mean Difference
Point estimate	-1.62
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.3
upper limit	-0.95

Secondary: Fecal Calprotectin by Week

End point title	Fecal Calprotectin by Week
End point description: Fecal calprotectin is an inflammatory marker for the gastrointestinal tract and considered as a measurement of neutrophil migration to the gastrointestinal tract. Higher values indicate more serious inflammation.	
End point type	Secondary
End point timeframe: Baseline and Weeks 8, 12 and 26	

End point values	Placebo	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	42	43	43	
Units: milligrams per kilogram (mg/kg)				
arithmetic mean (standard deviation)				
Baseline	380.43 (± 296.24)	351.39 (± 290.67)	399.33 (± 346.98)	
Week 8	440.81 (± 350.71)	295.39 (± 272.25)	283.76 (± 304.43)	
Week 12	441.4 (± 336.51)	351.59 (± 303.08)	194 (± 208.5)	
Week 26	939.11 (± 1037.39)	500.18 (± 337.83)	243.76 (± 219.04)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Fecal Calprotectin by Week

End point title	Change From Baseline in Fecal Calprotectin by Week

End point description:

Fecal calprotectin is an inflammatory marker for the gastrointestinal tract and considered as a measurement of neutrophil migration to the gastrointestinal tract. Higher values indicate more serious inflammation.

End point type	Secondary

End point timeframe:

Weeks 8, 12 and 26

End point values	Placebo	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	42	43	43	
Units: milligrams per kilogram (mg/kg)				
arithmetic mean (standard deviation)				
Week 8	69.22 (± 384.35)	-59.73 (± 216.36)	-123.95 (± 336.67)	
Week 12	103.55 (± 311.15)	-1.81 (± 228.24)	-107.04 (± 259.68)	
Week 26	579.1 (± 870.77)	154.17 (± 349.49)	-33.75 (± 204.25)	

Statistical analyses

Statistical analysis title	Analysis of Fecal Calprotectin
Statistical analysis description: Week 8	
Comparison groups	Placebo v Tofacitinib 5 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0566
Method	Linear mixed-effects model
Parameter estimate	Adjusted Mean Difference
Point estimate	-0.39
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.79
upper limit	0.01

Statistical analysis title	Analysis of Fecal Calprotectin
Statistical analysis description: Week 12	
Comparison groups	Placebo v Tofacitinib 5 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.3144
Method	Linear mixed-effects model
Parameter estimate	Adjusted Mean Difference
Point estimate	-0.21
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.61
upper limit	0.2

Statistical analysis title	Analysis of Fecal Calprotectin
Statistical analysis description: Week 26	
Comparison groups	Placebo v Tofacitinib 5 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0434
Method	Linear mixed-effects model
Parameter estimate	Adjusted Mean Difference
Point estimate	-0.56

Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.1
upper limit	-0.02

Statistical analysis title	Analysis of Fecal Calprotectin
Statistical analysis description:	
Week 8	
Comparison groups	Placebo v Tofacitinib 10 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.005
Method	Linear mixed-effects model
Parameter estimate	Adjusted Mean Difference
Point estimate	-0.57
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.96
upper limit	-0.18

Statistical analysis title	Analysis of Fecal Calprotectin
Statistical analysis description:	
Week 12	
Comparison groups	Placebo v Tofacitinib 10 mg BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0017
Method	Linear mixed-effects model
Parameter estimate	Adjusted Mean Difference
Point estimate	-0.66
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.06
upper limit	-0.25

Statistical analysis title	Analysis of Fecal Calprotectin
Statistical analysis description:	
Week 26	
Comparison groups	Placebo v Tofacitinib 10 mg BID

Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.0001
Method	Linear mixed-effects model
Parameter estimate	Adjusted Mean Difference
Point estimate	-1.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.72
upper limit	-0.67

Secondary: Tofacitinib Plasma Concentration by Nominal Post-Dose Sampling Time and Tofacitinib Dose

End point title	Tofacitinib Plasma Concentration by Nominal Post-Dose Sampling Time and Tofacitinib Dose[1]

End point description:

Plasma samples were collected from participants for the determination of tofacitinib concentrations. Only samples from tofacitinib-treated participants were subsequently analyzed. Plasma concentration data are summarized by nominal sample collection times specified in the protocol, and actual sample collection times may be different.

End point type	Secondary

End point timeframe:

Pre-dose, 20 minutes, 40 minutes, 1 hour and 2 hours post-dose at Weeks 12 and 26/early termination visit

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Inferential analyses were not performed for this endpoint. Only descriptive statistics (mean and standard deviation) for tofacitinib plasma concentration were presented.

End point values	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	48	48		
Units: nanograms per milliliter (ng/mL)				
arithmetic mean (standard deviation)				
Week 12, 0 hours (n=43, 40)	6.059 (± 7.4264)	6.832 (± 5.7271)		
Week 12, 20 minutes (n=45, 40)	31.56 (± 21.904)	58.53 (± 53.579)		
Week 12, 40 minutes (n=47, 41)	47.05 (± 23.904)	85.23 (± 43.726)		
Week 12, 1 hour (n=46, 42)	46.84 (± 20.365)	82.08 (± 33.779)		
Week 12, 2 hour (n=44, 42)	36.52 (± 14.81)	69.79 (± 23.274)		
Week 26/ET, 0 hours (n=43, 46)	6.183 (± 13.673)	9.51 (± 17.115)		
Week 26/ET, 20 minutes (n=45, 48)	40.98 (± 31.713)	60.48 (± 51.084)		
Week 26/ET, 40 minutes (n=46, 48)	55.83 (± 44.421)	85.66 (± 37.983)		

Week 26/ET, 1 hour (n=45, 48)	52.59 (± 42.291)	86.25 (± 30.948)		
Week 26/ET, 2 hours (n=44, 48)	39.09 (± 22.606)	64.15 (± 23.499)		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Serious adverse events (SAEs) were assessed from informed consent through and including 28 days after last dose of study treatment (30 weeks). Non-SAEs were recorded from time of first dose of study treatment through last participant visit (30 weeks).

Adverse event reporting additional description:

The same event may appear as both an adverse event (AE) and an SAE. However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as non-serious in another participant, or 1 participant may have experienced both a serious and non-serious event during the study.

Assessment type	Non-systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	18.0

Reporting groups

Reporting group title	Tofacitinib 5 mg BID

Reporting group description:

Tofacitinib 5 mg (one placebo tablet and one tofacitinib tablet) for oral administration at a dose of 5 mg BID for 26 weeks.

Reporting group title	Placebo

Reporting group description:

Placebo (two placebo tablets) to match tofacitinib for oral administration BID for 26 weeks.

Reporting group title	Tofacitinib 10 mg BID

Reporting group description:

Tofacitinib 10 mg (two tofacitinib tablets) for oral administration at a dose of 10 mg BID for 26 weeks.

Serious adverse events	Tofacitinib 5 mg BID	Placebo	Tofacitinib 10 mg BID
Total subjects affected by serious adverse events			
subjects affected / exposed	6 / 60 (10.00%)	7 / 59 (11.86%)	8 / 61 (13.11%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Injury, poisoning and procedural complications			
Intestinal anastomosis complication			
subjects affected / exposed	1 / 60 (1.67%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
Abortion induced			
subjects affected / exposed	0 / 60 (0.00%)	1 / 59 (1.69%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 60 (0.00%)	1 / 59 (1.69%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	0 / 60 (0.00%)	0 / 59 (0.00%)	1 / 61 (1.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Crohn’s disease			
subjects affected / exposed	0 / 60 (0.00%)	3 / 59 (5.08%)	2 / 61 (3.28%)
occurrences causally related to treatment / all	0 / 0	1 / 3	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 60 (0.00%)	1 / 59 (1.69%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	0 / 60 (0.00%)	0 / 59 (0.00%)	1 / 61 (1.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal fistula			
subjects affected / exposed	0 / 60 (0.00%)	0 / 59 (0.00%)	1 / 61 (1.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	1 / 60 (1.67%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine perforation			

subjects affected / exposed	1 / 60 (1.67%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	0 / 60 (0.00%)	0 / 59 (0.00%)	1 / 61 (1.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis acute			
subjects affected / exposed	0 / 60 (0.00%)	1 / 59 (1.69%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Nephrolithiasis			
subjects affected / exposed	0 / 60 (0.00%)	0 / 59 (0.00%)	1 / 61 (1.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Anal abscess			
subjects affected / exposed	1 / 60 (1.67%)	0 / 59 (0.00%)	1 / 61 (1.64%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile colitis			
subjects affected / exposed	1 / 60 (1.67%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile infection			
subjects affected / exposed	1 / 60 (1.67%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 60 (0.00%)	0 / 59 (0.00%)	1 / 61 (1.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Rectal abscess			
subjects affected / exposed	1 / 60 (1.67%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	1 / 60 (1.67%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 2 %

Non-serious adverse events	Tofacitinib 5 mg BID	Placebo	Tofacitinib 10 mg BID
Total subjects affected by non-serious adverse events			
subjects affected / exposed	40 / 60 (66.67%)	28 / 59 (47.46%)	35 / 61 (57.38%)
Investigations			
Blood creatine phosphokinase increased			
subjects affected / exposed	2 / 60 (3.33%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences (all)	2	0	0
Blood creatinine increased			
subjects affected / exposed	2 / 60 (3.33%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences (all)	2	0	0
Blood pressure increased			
subjects affected / exposed	0 / 60 (0.00%)	0 / 59 (0.00%)	2 / 61 (3.28%)
occurrences (all)	0	0	2
Lymphocyte count decreased			
subjects affected / exposed	2 / 60 (3.33%)	0 / 59 (0.00%)	1 / 61 (1.64%)
occurrences (all)	2	0	1
Injury, poisoning and procedural complications			
Tooth fracture			
subjects affected / exposed	2 / 60 (3.33%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences (all)	2	0	0
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 60 (0.00%)	0 / 59 (0.00%)	2 / 61 (3.28%)
occurrences (all)	0	0	2

Nervous system disorders			
Headache			
subjects affected / exposed	4 / 60 (6.67%)	2 / 59 (3.39%)	2 / 61 (3.28%)
occurrences (all)	4	2	2
Paraesthesia			
subjects affected / exposed	0 / 60 (0.00%)	0 / 59 (0.00%)	2 / 61 (3.28%)
occurrences (all)	0	0	2
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	3 / 60 (5.00%)	0 / 59 (0.00%)	5 / 61 (8.20%)
occurrences (all)	3	0	5
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	2 / 60 (3.33%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences (all)	3	0	0
Chest pain			
subjects affected / exposed	0 / 60 (0.00%)	0 / 59 (0.00%)	2 / 61 (3.28%)
occurrences (all)	0	0	2
Fatigue			
subjects affected / exposed	2 / 60 (3.33%)	1 / 59 (1.69%)	1 / 61 (1.64%)
occurrences (all)	2	1	1
Pyrexia			
subjects affected / exposed	2 / 60 (3.33%)	2 / 59 (3.39%)	4 / 61 (6.56%)
occurrences (all)	3	2	6
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	5 / 60 (8.33%)	2 / 59 (3.39%)	4 / 61 (6.56%)
occurrences (all)	5	2	4
Abdominal pain lower			
subjects affected / exposed	2 / 60 (3.33%)	0 / 59 (0.00%)	1 / 61 (1.64%)
occurrences (all)	2	0	1
Abdominal tenderness			
subjects affected / exposed	2 / 60 (3.33%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences (all)	2	0	0
Crohn’s disease			

subjects affected / exposed	11 / 60 (18.33%)	10 / 59 (16.95%)	7 / 61 (11.48%)
occurrences (all)	11	11	10
Diarrhoea			
subjects affected / exposed	3 / 60 (5.00%)	0 / 59 (0.00%)	5 / 61 (8.20%)
occurrences (all)	3	0	5
Dyspepsia			
subjects affected / exposed	2 / 60 (3.33%)	3 / 59 (5.08%)	1 / 61 (1.64%)
occurrences (all)	2	3	1
Haemorrhoids			
subjects affected / exposed	2 / 60 (3.33%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences (all)	3	0	0
Nausea			
subjects affected / exposed	1 / 60 (1.67%)	1 / 59 (1.69%)	2 / 61 (3.28%)
occurrences (all)	1	1	2
Toothache			
subjects affected / exposed	0 / 60 (0.00%)	0 / 59 (0.00%)	2 / 61 (3.28%)
occurrences (all)	0	0	2
Reproductive system and breast disorders			
Endometriosis	Additional description: Subjects exposed are only females since this AE can only occur in females.		
subjects affected / exposed[1]	0 / 30 (0.00%)	0 / 32 (0.00%)	1 / 24 (4.17%)
occurrences (all)	0	0	1
Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	0 / 60 (0.00%)	1 / 59 (1.69%)	2 / 61 (3.28%)
occurrences (all)	0	1	2
Eczema			
subjects affected / exposed	2 / 60 (3.33%)	1 / 59 (1.69%)	0 / 61 (0.00%)
occurrences (all)	2	1	0
Rash			
subjects affected / exposed	0 / 60 (0.00%)	2 / 59 (3.39%)	0 / 61 (0.00%)
occurrences (all)	0	3	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	6 / 60 (10.00%)	2 / 59 (3.39%)	4 / 61 (6.56%)
occurrences (all)	6	2	5

Back pain			
subjects affected / exposed	2 / 60 (3.33%)	1 / 59 (1.69%)	2 / 61 (3.28%)
occurrences (all)	3	1	3
Torticollis			
subjects affected / exposed	2 / 60 (3.33%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences (all)	2	0	0
Infections and infestations			
Bronchitis			
subjects affected / exposed	3 / 60 (5.00%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences (all)	3	0	0
Conjunctivitis			
subjects affected / exposed	0 / 60 (0.00%)	1 / 59 (1.69%)	3 / 61 (4.92%)
occurrences (all)	0	1	3
Folliculitis			
subjects affected / exposed	0 / 60 (0.00%)	0 / 59 (0.00%)	3 / 61 (4.92%)
occurrences (all)	0	0	4
Gastroenteritis			
subjects affected / exposed	2 / 60 (3.33%)	0 / 59 (0.00%)	3 / 61 (4.92%)
occurrences (all)	2	0	3
Herpes zoster			
subjects affected / exposed	0 / 60 (0.00%)	0 / 59 (0.00%)	2 / 61 (3.28%)
occurrences (all)	0	0	2
Influenza			
subjects affected / exposed	5 / 60 (8.33%)	2 / 59 (3.39%)	3 / 61 (4.92%)
occurrences (all)	6	3	4
Nasopharyngitis			
subjects affected / exposed	11 / 60 (18.33%)	4 / 59 (6.78%)	5 / 61 (8.20%)
occurrences (all)	11	4	5
Oral herpes			
subjects affected / exposed	1 / 60 (1.67%)	2 / 59 (3.39%)	0 / 61 (0.00%)
occurrences (all)	1	2	0
Sinusitis			
subjects affected / exposed	2 / 60 (3.33%)	0 / 59 (0.00%)	1 / 61 (1.64%)
occurrences (all)	2	0	1
Tooth abscess			

subjects affected / exposed	2 / 60 (3.33%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences (all)	2	0	0
Upper respiratory tract infection			
subjects affected / exposed	1 / 60 (1.67%)	2 / 59 (3.39%)	1 / 61 (1.64%)
occurrences (all)	1	2	2
Urinary tract infection			
subjects affected / exposed	6 / 60 (10.00%)	4 / 59 (6.78%)	8 / 61 (13.11%)
occurrences (all)	11	5	8
Vaginal infection	Additional description: Subjects exposed are only females since this AE can only occur in females.		
subjects affected / exposed[2]	0 / 30 (0.00%)	0 / 32 (0.00%)	1 / 24 (4.17%)
occurrences (all)	0	0	1
Vulvovaginal mycotic infection	Additional description: Subjects exposed are only females since this AE can only occur in females.		
subjects affected / exposed[3]	0 / 30 (0.00%)	0 / 32 (0.00%)	1 / 24 (4.17%)
occurrences (all)	0	0	1
Metabolism and nutrition disorders			
Hypercholesterolaemia			
subjects affected / exposed	0 / 60 (0.00%)	0 / 59 (0.00%)	2 / 61 (3.28%)
occurrences (all)	0	0	2
Hyperlipidaemia			
subjects affected / exposed	0 / 60 (0.00%)	0 / 59 (0.00%)	2 / 61 (3.28%)
occurrences (all)	0	0	2
Hypokalaemia			
subjects affected / exposed	1 / 60 (1.67%)	0 / 59 (0.00%)	2 / 61 (3.28%)
occurrences (all)	1	0	2

Notes:

[1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Male subject are excluded from the total number. Exposed subjects are only females since this AE can only occur in females.
[2] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Male subject are excluded from the total number. Exposed subjects are only females since this AE can only occur in females.
[3] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Male subject are excluded from the total number. Exposed subjects are only females since this AE can only occur in females.

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
14 September 2011	This amendment was produced primarily to correct an error in the first question of the CDAI, the primary endpoint assessment tool, for the study, to add the word "very" before the words "soft stools". This word was inadvertently omitted in the first version of the protocol. Language regarding publication policy was also added to meet requirements for all countries involved in this study. The opportunity was then taken to also correct other minor typographical errors and to clarify some language that was felt to be imprecise or unclear in the protocol.
28 September 2012	This amendment updated standard Pfizer protocol text, including safety language in various sections, including Administration, Reproductive Status of Female Subjects, and Adverse Event Reporting. This amendment also included an updated prohibited medications table, lymphocyte count requirement for participant selection and monitoring and discontinuation criteria for lymphopenia, guidance regarding surgery during the study, and updated to the Background section among other revisions.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported